Boehringer Ingelheim/Pfizer’s Spiriva Has Earned Decision Resources’ Proprietary Clinical Gold Standard Status for the Treatment of Chronic Obstructive Pulmonary Disease

The COPD Drug Market Will Increase from Approximately $8 Billion in 2010 to $13 Billion in 2020, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical data and the opinions of interviewed thought leaders, Boehringer Ingelheim/Pfizer’s Spiriva has earned Decision Resources’ proprietary clinical gold standard status for the treatment of chronic obstructive pulmonary disease (COPD), on the basis of its clinical profile which is the strongest among the key products analyzed. Through 2020, Decision Resources does not expect any therapy in development to replace Spiriva as the clinical gold standard. While some emerging therapies hold promise, they have efficacy, safety and tolerability, and/or delivery features that prevent them from displacing Spiriva.

“Clinical data and the opinions of interviewed thought leaders indicate that key current and emerging therapies have no advantage over sales-leading Spiriva on this attribute”

Decision Resources’ analysis of the COPD drug market also finds that surveyed U.S. pulmonologists and managed care organization pharmacy directors agree that a therapy’s ability to reduce the frequency of exacerbations is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in COPD.

“Clinical data and the opinions of interviewed thought leaders indicate that key current and emerging therapies have no advantage over sales-leading Spiriva on this attribute,” said Decision Resources Analyst Edward Wydysh, Ph.D.

The findings also reveal that surveyed U.S. pulmonologists indicate that they would prescribe Boehringer Ingelheim’s olodaterol/tiotropium and Novartis/Eisai’s indacaterol/glycopyrronium each to 25 percent of their COPD patients. However, Decision Resources forecasts that olodaterol/tiotropium will earn a patient share of only approximately 7 percent in the U.S. drug-treated COPD market by 2020 owing to, among other constraints, the competition it will likely face from other once-daily bronchodilators. Additionally, indacaterol/glycopyrronium is forecast to earn a patient share of only about 4 percent in the U.S. drug-treated COPD market by 2020 owing to considerable competition from other long-acting bronchodilators.

The market for chronic obstructive pulmonary disease totaled more than $8 billion in 2010 and will experience steady annual growth, increasing to approximately $13 billion in 2020. An expanding aging population and increases in diagnosis and drug treatment will fuel growth in the COPD market as the drug-treated population is expected to expand from nearly 19 million patients in 2010 to nearly 25 million patients in 2020 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

Decision Resources’ Robust Market Forecast and Opportunities Analysis

Decision Resources provides a comprehensive view of what is happening in a specific drug market now and in the decade ahead. The research includes analysis of the unmet need and near-term drug development opportunities that exist within a drug market powered by primary research from physicians and payers. The robust market forecast and opportunities analysis is comprised of the Pharmacor 2012 advisory service and the DecisionBase 2012 report series.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.